RhIL-11 effectively restores platelet counts in 12,431 cancer patients with therapy-induced thrombocytopenia
Background
Cancer therapy-induced thrombocytopenia (CTIT) is a significant complication of chemotherapy, often leading to dose reductions, treatment delays, or discontinuation, and increasing the risk of severe bleeding. Current standard-of-care options are limited, with recombinant human interleukin-11 (rhIL-11) and recombinant human thrombopoietin (rhTPO) being the primary approved therapeutic agents. RhIL-11 stimulates the proliferation and differentiation of megakaryocyte progenitor cells via the IL-11 receptor, thereby increasing platelet production. This study addresses the need for large-scale, real-world data to validate rhIL-11's efficacy and safety across diverse patient populations and tumor types.
Study Design
This multicenter retrospective study analyzed 12,431 CTIT patients treated with rhIL-11 across 58 Chinese medical centers between July 2023 and June 2024. The study aimed to characterize CTIT profiles and evaluate rhIL-11's efficacy and safety in a real-world setting. Researchers used multivariate logistic regression analysis to identify independent risk factors for CTIT. Treatment outcomes, including platelet recovery times and response rates, were assessed, alongside the incidence and nature of adverse events (AEs). The mean treatment duration for rhIL-11 was 6.79 ± 2.59 days.
Results
Independent risk factors for CTIT included advanced age, specific medical histories, prior myelosuppression, tumor type, bone marrow involvement, and previous anti-tumor therapy. RhIL-11 demonstrated significant thrombopoietic effects, with patients achieving platelet (PLT) recovery to 50 × 10^9/L in a mean of 4.60 ± 4.40 days and to 100 × 10^9/L in 7.68 ± 5.09 days. Hematologic malignancy patients required longer treatment and slower PLT recovery compared to those with solid tumors. Urologic and head/neck malignancy patients exhibited faster recovery, while uterine, colorectal, and liver cancer patients showed poorer outcomes. Fluoropyrimidine monotherapy delayed PLT recovery compared to platinum-, taxane-, anthracycline-based regimens, or gemcitabine/platinum combinations (all p < 0.05). Patients with 'impaired' PLT recovery capacity or grade IV CTIT demonstrated longer treatment and PLT recovery times, while grade I/III CTIT was associated with higher PLT recovery response rates. AEs occurred in 28.9% of patients, primarily mild fatigue (15.3%) and edema (7.5%). COVID-19 infection correlated with prolonged treatment duration and delayed PLT normalization.
RhIL-11 treatment led to platelet recovery to 50 × 10^9/L in just 4.60 days and to 100 × 10^9/L in 7.68 days across a large cohort of 12,431 CTIT patients.
Key Findings
- RhIL-11 effectively restored platelet counts, with recovery to 50 × 10^9/L in 4.60 days and 100 × 10^9/L in 7.68 days.
- Adverse events occurred in 28.9% of patients, predominantly mild fatigue (15.3%) and edema (7.5%).
- Hematologic malignancy patients required longer rhIL-11 treatment and slower platelet recovery than solid tumor patients.
- Fluoropyrimidine monotherapy delayed platelet recovery compared to platinum-, taxane-, or anthracycline-based regimens (p < 0.05).
- COVID-19 infection was associated with prolonged rhIL-11 treatment duration and delayed platelet normalization.
Why It Matters
This large-scale, real-world study provides robust validation for rhIL-11 as an effective and acceptably tolerated treatment for cancer therapy-induced thrombocytopenia (CTIT). The findings underscore the importance of individualized CTIT management strategies, recognizing that patient subgroups (e.g., tumor type, prior treatments, CTIT grade) respond differently. For clinicians and patients, this means tailoring rhIL-11 use based on specific patient profiles could optimize outcomes and minimize treatment delays. The detailed safety profile, with AEs in 28.9% primarily being mild fatigue and edema, reinforces its tolerability. Proactive monitoring for adverse events and considering factors like concurrent infections (e.g., COVID-19) are crucial for maximizing treatment success and patient safety.
rhil-11
cancer-therapy-induced-thrombocytopenia
thrombocytopenia
hematologic-malignancy
solid-tumors
cytokine